Virax Biolabs Group Ltd. has released its financial results for the fiscal year ending March 31, 2025. The company reported revenues of $6.331 million, a significant decrease from $156.419 million in the previous year, 2024. The cost of revenues also saw a reduction, recorded at $59.398 million for 2025 compared to $105.829 million in 2024. Virax Biolabs experienced a gross loss of $53.067 million in 2025, contrasting with a gross profit of $50.590 million in 2024. Operating expenses included general and administrative costs of $4.330 million, slightly down from $4.595 million the previous year. Research and Development expenses were $1.780 million in 2025, compared to $1.562 million in 2024. Notably, there was no impairment of intangible assets in 2025, whereas 2024 saw an impairment of $390,355. Virax Biolabs, a global biotechnology firm focused on viral disease prevention, detection, and diagnosis, continues to emphasize its development in T cell in vitro diagnostics. The company does not provide specific guidance or outlook, citing the unpredictability of outcomes in its research and development efforts.